Last reviewed 2026-04-23 · How we verify

VIR-7831

VIR-7831 is a monoclonal antibody that targets the SARS-CoV-2 spike protein.

VIR-7831 is a monoclonal antibody that targets the SARS-CoV-2 spike protein. Used for Prevention of COVID-19.

At a glance

Mechanism of action

It works by binding to the spike protein, preventing the virus from entering host cells. This neutralization prevents the virus from causing infection and replication.

Approved indications

• Prevention of COVID-19

Common side effects

• Injection site pain
• Fatigue
• Headache

Key clinical trials

• AGILE (Early Phase Platform Trial for COVID-19) (PHASE1, PHASE2)
• PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V (PHASE2, PHASE3)
• Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study (PHASE1)
• A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 in Immunocompromised Individuals (PHASE2)
• Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19. (PHASE3)
• VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) (PHASE3)
• ACTIV-3: Therapeutics for Inpatients With COVID-19 (PHASE3)
• Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19 (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• VIR-7831 CI brief — competitive landscape report
• VIR-7831 updates RSS · CI watch RSS
• National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI